PriceTargets.com logo

Alpha Cognition - ACOGF Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: C$0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$0.00 As of 11/4/2024 10:07 PM ET
+0 (0.00%)

This chart shows the closing price for ACOGF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alpha Cognition Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACOGF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACOGF

Analyst Price Target is C$0.00
This price target is based on 0 analysts offering 12 month price targets for Alpha Cognition in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a NaN upside from the last price of C$0.00.

This chart shows the closing price for ACOGF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Alpha Cognition. This rating has held steady since January 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/22/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/15/2024Raymond JamesUpgradeHold ➝ Moderate Buy
2/10/2023Raymond JamesDowngradeOutperform ➝ Market Perform
9/1/2022Raymond JamesLower TargetOutperform ➝ Outperform$4.00 ➝ $3.00
(Data available from 5/22/2020 forward)

News Sentiment Rating

0.81 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/24/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/23/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/22/2025
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/21/2025
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/23/2025
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/22/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2025

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Alpha Cognition logo
Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: N/A

50 Day Range

MA: C$1.05
Low: C$0.35
High: C$9.44

52 Week Range

Now: N/A

Volume

179,500 shs

Average Volume

78,954 shs

Market Capitalization

C$52.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Alpha Cognition?

The following Wall Street sell-side analysts have issued stock ratings on Alpha Cognition in the last twelve months: Raymond James.
View the latest analyst ratings for ACOGF.

What is the current price target for Alpha Cognition?

0 Wall Street analysts have set twelve-month price targets for Alpha Cognition in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Alpha Cognition in the next year.
View the latest price targets for ACOGF.

What is the current consensus analyst rating for Alpha Cognition?

Alpha Cognition currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ACOGF.

What other companies compete with Alpha Cognition?

Other companies that are similar to Alpha Cognition include Prime Medicine, Tevogen Bio, Genfit, SOPHiA GENETICS and CARGO Therapeutics. Learn More about companies similar to Alpha Cognition.

How do I contact Alpha Cognition's investor relations team?

Alpha Cognition's physical mailing address is 1228 Hamilton Street Suite 301, Vancouver BC, V6B 6L2. The company's listed phone number is 604-564-9244 and its investor relations email address is [email protected]. The official website for Alpha Cognition is www.alphacognition.com. Learn More about contacing Alpha Cognition investor relations.